Insulin peglispro
A long-acting insulin made by attaching a large PEG chain to insulin lispro, which beat glargine on blood sugar but raised liver fat and triglycerides
Insulin peglispro, known in trials as basal insulin peglispro (BIL) or LY2605541, is insulin lispro with a 20 kDa polyethylene glycol chain fixed to one lysine. The bulky chain slows its absorption and removal, giving a half-life of two to three days and a nearly flat profile, and it limits how much insulin reaches muscle and fat compared with the liver. In eight phase 3 IMAGINE trials it lowered HbA1c more than glargine with less night-time hypoglycaemia, but it also raised liver enzymes, liver fat and triglycerides. Development was stopped, and it was never approved.
Used in human trials: 0.33 to 1.00 U/kg, Once daily, Subcutaneous (Study: fixed daily doses, type 2 diabetes (phase 1)) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Insulin from the pancreas reaches the liver first, through the portal vein, so in normal physiology the liver gets a stronger insulin signal than muscle and fat. Insulin injected under the skin enters the general circulation instead and flattens that gradient. Lilly designed insulin peglispro to restore some of it. Attaching a 20 kDa PEG chain to insulin lispro gave the molecule a large hydrodynamic size, which slows its absorption and clearance and, by the developers' account, limits how much reaches muscle and fat while the liver still responds.
Clamp studies bore that out. In healthy men and in people with type 1 diabetes, doses of peglispro that suppressed the liver's glucose output as much as glargine did drove far less glucose uptake into peripheral tissue, and it suppressed fat breakdown less. A dog study found the same liver-preferring pattern. Pharmacokinetic studies showed a half-life of roughly two to three days at steady state, a nearly peakless profile within seven to ten days, low variability from day to day, and no need to change the dose for kidney impairment.
Phase 2 trials looked promising: blood glucose control similar to or better than glargine, lower night-time hypoglycaemia, less variation in glucose, and modest weight loss rather than gain. The phase 3 IMAGINE programme then enrolled several thousand people with type 1 and type 2 diabetes. Across the trials, peglispro lowered HbA1c by 0.2 to 0.5 percentage points more than glargine, cut nocturnal hypoglycaemia by roughly 36% to 60%, tolerated wide swings in dosing time and caused much less hypoglycaemia than glargine after a deliberate double dose. A meta-analysis of cardiovascular events found no excess.
The same trials kept finding a cost. Alanine aminotransferase, a marker of liver injury, rose on peglispro and fell back after stopping; more patients had values three times the upper limit, though no case met the criteria for serious drug-induced liver injury. MRI showed liver fat rising on peglispro in previously treated patients and failing to fall in insulin-naive ones, while it fell or held on glargine. Triglycerides rose, injection-site reactions were more common, and in type 1 diabetes total and daytime hypoglycaemia increased. The likely explanation is the design itself: with less insulin reaching fat tissue, more fatty acids flow to the liver.
Lilly stopped development after regulators and outside experts reviewed the liver data. Insulin peglispro was never submitted for approval, and Drugs@FDA has no record of it. It matters now mainly as a lesson for newer once-weekly insulins: a liver-preferring design changed lipid and liver handling in ways that HbA1c alone did not show.
Mechanism of Action
Insulin peglispro acts on the insulin receptor like any insulin; its 20 kDa PEG chain changes where and how long it acts.
Slow absorption and clearance
A large hydrodynamic size delays absorption and clearance, giving a 2 to 3 day half-life and a flat profile (PMIDs 24504686, 24118909).
Liver over periphery
It suppresses liver glucose output like glargine but drives much less uptake in muscle and fat (PMIDs 24947791, 27723226).
Less brake on fat breakdown
Weaker suppression of lipolysis is thought to send more fatty acids to the liver, raising triglycerides and liver fat (PMIDs 27723226, 27486125).
Published Research
Studies of insulin peglispro read from their PubMed abstracts: the phase 3 IMAGINE trials and their pooled analyses of hypoglycaemia, lipids, the liver and cardiovascular events, the phase 2 trials, pharmacokinetic and clamp studies in people, two reviews, and animal work. Some papers use its code, LY2605541.
IMAGINE 1: type 1 diabetes, open label
455 adults with type 1 diabetes used bedtime peglispro or glargine with mealtime lispro. At 26 weeks HbA1c was 7.06% against 7.43%, nocturnal hypoglycaemia was 36% lower and weight fell, but total hypoglycaemia was 29% higher, severe hypoglycaemia more common, and ALT, triglycerides and injection-site reactions rose.
IMAGINE 3: type 1 diabetes, blinded
In 1,114 adults followed for 52 weeks, HbA1c was 7.38% against 7.61% on glargine, nocturnal hypoglycaemia 47% lower and total hypoglycaemia 11% higher. Weight fell 1.8 kg relative to glargine, while triglycerides and ALT rose more and injection-site reactions were more frequent.
IMAGINE 2: insulin-naive type 2 diabetes
Added to oral drugs for 52 or 78 weeks in a double-blind trial, peglispro lowered HbA1c 0.29 points more than glargine with 26% less nocturnal hypoglycaemia. Triglycerides, ALT and AST were higher, liver fat did not change while it fell 3.1% on glargine, and injection-site reactions were more common (3.5% against 0.6%).
IMAGINE 4: type 2 diabetes with mealtime insulin
In 1,369 patients using lispro at meals, HbA1c fell to 6.8% against 7.0% on glargine at 26 weeks, nocturnal hypoglycaemia was lower (0.51 against 0.92 events per 30 days) and weight gain smaller, but daytime hypoglycaemia and triglyceride and aminotransferase levels were higher.
IMAGINE 5: switching from another basal insulin
In 466 people with type 2 diabetes already on basal insulin, HbA1c fell 0.82 points on peglispro against 0.29 on glargine at 26 weeks, nocturnal hypoglycaemia was 60% lower, and the advantage held to 52 weeks. Triglycerides, aminotransferases and MRI liver fat rose more on peglispro.
IMAGINE 6: against NPH insulin
In 641 insulin-naive patients with type 2 diabetes, morning or bedtime peglispro lowered HbA1c 0.37 points more than bedtime NPH, to 6.8% against 7.1%, with less nocturnal hypoglycaemia and similar total hypoglycaemia; ALT rose on peglispro without signs of severe liver injury.
IMAGINE 7: flexible dosing times
In a crossover study of 212 people with type 1 diabetes, injecting peglispro at intervals varying from 8 to 40 hours gave HbA1c and hypoglycaemia rates similar to injecting at the same time every day.
IMAGINE 8: a deliberate double dose
In 68 insulin-treated patients with type 2 diabetes kept in hospital, a single double dose caused clinically significant hypoglycaemia within 84 hours in 6.6% on peglispro against 35.5% on glargine.
Insulin-naive Asian patients
In 388 Asian patients with type 2 diabetes starting insulin, peglispro lowered HbA1c 1.6 points against 1.4 for glargine at 26 weeks with less weight gain, similar hypoglycaemia, more adverse events overall and higher aminotransferases.
Pooled hypoglycaemia data
Pooling 4,927 patients from five phase 3 trials against glargine, nocturnal hypoglycaemia was 36% to 45% lower on peglispro despite better HbA1c. Total hypoglycaemia was 15% higher in type 1 diabetes, and daytime events were higher in patients using mealtime insulin; severe hypoglycaemia did not differ.
Pooled lipid data
Across six IMAGINE trials, peglispro barely changed LDL and HDL cholesterol. When it replaced glargine or NPH, triglycerides rose; in insulin-naive patients they stayed flat on peglispro but fell on the comparators. The authors linked this to less suppression of fat breakdown outside the liver.
Pooled liver data
In 5,371 patients from seven trials, ALT on peglispro was 7 IU/L higher than on glargine at 52 weeks and fell after stopping; more patients exceeded three times the upper limit, but none met the criteria for drug-caused serious liver injury. Liver fat on MRI was 2.2 to 5.3 points higher than with glargine.
Cardiovascular events: no excess
A prespecified meta-analysis of one phase 2 and six phase 3 trials (5,862 patients) found no difference in major cardiovascular events between peglispro and comparator insulins (hazard ratio 0.82) and no difference in deaths.
Phase 2: type 2 diabetes
In 290 patients switched to morning dosing, peglispro and glargine gave similar fasting glucose and HbA1c at 12 weeks. Peglispro reduced within-day glucose swings and produced weight loss of 0.6 kg against a 0.3 kg gain; aminotransferases were higher but within normal limits.
Phase 2: type 1 diabetes crossover
137 people with type 1 diabetes used each basal insulin for 8 weeks. Peglispro lowered mean daily glucose (144 against 152 mg/dL), cut mealtime insulin and weight (-1.2 against +0.7 kg), lowered nocturnal but raised total hypoglycaemia, and caused more gut complaints and higher liver enzymes and triglycerides.
Continuous glucose monitoring
In a phase 2 subgroup with type 2 diabetes wearing glucose monitors, fewer patients on peglispro had hypoglycaemia (50% against 78%) and they spent less time at or below 70 mg/dL, both overall and at night.
Why weight fell
Exploratory analyses of two phase 2 trials found weight loss in 57% of type 2 and 66% of type 1 patients on peglispro against about 40% on glargine; the change was unrelated to baseline BMI or to hypoglycaemia.
Single doses in healthy subjects
After single subcutaneous doses, peglispro peaked at 18 to 42 hours and had a half-life of 24 to 46 hours, against 12 to 15 hours for glargine, and its glucose-lowering effect lasted at least 36 hours; given intravenously its half-life was 2.3 hours.
Steady state in type 2 diabetes
Fixed daily doses of 0.33 to 1.00 U/kg for 14 days reached steady state in 7 to 10 days with a half-life of 45 to 76 hours and a peak-to-trough ratio under 2, giving a nearly peakless glucose-lowering profile; mild hypoglycaemia was the main adverse event.
Kidney impairment
After a single 0.33 U/kg dose, clearance and half-life were the same across normal kidney function, every stage of impairment and dialysis; one dialysis session removed 13%, and no dose change was judged necessary.
Liver-preferring action in healthy men
In euglycaemic clamps in eight healthy men, peglispro suppressed the liver's glucose output as glargine did but raised peripheral glucose disposal far less, showing relatively greater action on the liver.
Liver-preferring action in type 1 diabetes
Infused into people with type 1 diabetes, peglispro and glargine suppressed liver glucose output equally at the lower dose, but glargine drove 2.4 times the peripheral glucose disposal, and peglispro suppressed fat breakdown less.
Glucose clamps at steady state
In 23 people with type 1 diabetes after 8 weeks on each insulin (mean 0.42 U/kg), daily glucose and hypoglycaemia were similar, but less glucose had to be infused per unit of peglispro, consistent with lower peripheral action.
How a good idea failed
This review describes peglispro's flat profile, 2 to 3 day half-life and liver preference, its better glucose control and lower nocturnal hypoglycaemia than glargine in phase 3, and the higher aminotransferases and triglycerides that led Lilly to stop development after regulators and outside experts reviewed the liver data.
Early review
Written during phase 2, this review set out the rationale for a large, slowly absorbed insulin, its low mitogenic potency in preclinical work, its weight advantage and its early signals of raised transaminases and changed lipids, and called for full evaluation of its risks.
Liver preference in dogs
In conscious dogs under clamp conditions, peglispro shifted the liver from releasing to taking up glucose while raising glucose uptake elsewhere far less than regular insulin, resembling the action of insulin secreted by the pancreas.
What happens to the molecule in rats
In rats, subcutaneous bioavailability was 23% to 29%; the insulin part was broken down extensively, the iodine label left mainly in urine, and the PEG chain was excreted, largely with one lysine still attached, in urine and faeces.
Long-term toxicology
Daily injections for 52 weeks in rats and 39 weeks in dogs, at 4 to 6 times typical clinical exposure, produced no tumours or overgrowth and no PEG-related vacuoles in macrophages, kidney or brain lining cells; fat thickening at injection sites was more frequent than with NPH.
Dosing Data
Insulin peglispro was never approved, so there is no label. In the phase 3 trials it was titrated to each patient's fasting glucose, like any basal insulin, and the abstracts give no fixed amount. These rows are amounts given in the pharmacology studies carded above.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Insulin peglispro is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: subcutaneous). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.
Source: the route and amount of each dose row in Dosing Data below.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Insulin peglispro, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Insulin peglispro stays intact once mixed.
How it is taken
As it was given in human studies: Subcutaneous (Once daily; Study: fixed daily doses, type 2 diabetes (phase 1)).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of 44.7 to 75.5 hours at steady state, about 2 to 3 days (PMID 24118909). After about five half-lives almost none is left.
How long the doses were given: Study: fixed daily doses, type 2 diabetes (phase 1): 14 days, no titration; Study: titrated doses, type 1 diabetes (phase 2 clamp substudy): 8 weeks; Study: single dose across kidney function (phase 1): Single dose.
When effects appear: unknown; no source on this page gives a time to effect for Insulin peglispro. Results reported in the studies are under Published Research.
Source: half-life: PMID 24118909; Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Higher ALT and AST, with more values above three times normal, falling after stopping (PMID 27723227); Rising or unimproved liver fat on MRI compared with glargine (PMIDs 27349219, 26577417); Higher triglycerides when it replaced other insulins (PMID 27486125); More injection-site reactions (PMIDs 27349219, 27265390); More total and daytime hypoglycaemia in type 1 diabetes and with mealtime insulin, despite less at night (PMID 27484021). Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Insulin peglispro. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the phase 2 and 3 trials and pooled analyses above”).
Interactions
Unknown: a PubMed search for human interaction studies of Insulin peglispro (reviewed 2026-10-28) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Insulin peglispro products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Discontinued (Never approved). Sport: Prohibited at all times (S4.4.2).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the phase 2 and 3 trials and pooled analyses above.
Contraindications & Cautions
No product label exists. These cautions follow from the evidence.
Legal Status
Insulin peglispro was an investigational insulin; it has not been approved anywhere in the sources read.
Frequently Asked Questions
?What was insulin peglispro?
A basal insulin made by attaching a 20 kDa PEG chain to insulin lispro. It was designed to last more than a day per injection and to act more on the liver than on muscle and fat.
?Did it control blood sugar?
Yes. In phase 3 it lowered HbA1c more than glargine and NPH, with clearly less night-time hypoglycaemia.
?Why was it dropped?
It raised liver enzymes, liver fat and triglycerides compared with glargine. After regulators and outside experts reviewed the liver data, Lilly ended development.
?Why did patients lose weight?
Phase 2 trials found weight loss more often than with glargine. The mechanism is not settled; weight change was not explained by baseline BMI or hypoglycaemia.
?Is there a dose I could use?
No. It was never approved, and in trials it was titrated to each patient's glucose like any insulin. The amounts on this page are study doses.
?How does it relate to today's weekly insulins?
Insulin icodec and other once-weekly insulins are different molecules. Peglispro's history shows why their liver and lipid effects are watched closely.
References
- [registry] ClinicalTrials.gov API v2, read October 29, 2026: 13 studies of insulin peglispro sponsored by Eli Lilly and Company, including IMAGINE 4 (NCT01468987), IMAGINE 5 (NCT01582451), IMAGINE 7 (NCT01792284) and IMAGINE 8 (NCT02132637), all completed, and NCT02106364 (phase 3, withdrawn, 0 participants).
- [clinical-trial] Garg S, et al. "A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1." Diabetes Obes Metab, 2016;18 Suppl 2:25-33. PMID: 27393697.
- [clinical-trial] Bergenstal RM, et al. "Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3." Diabetes Obes Metab, 2016;18(11):1081-1088. PMID: 27265390.
- [clinical-trial] Davies MJ, et al. "Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial." Diabetes Obes Metab, 2016;18(11):1055-1064. PMID: 27349219.
- [clinical-trial] Blevins T, et al. "Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4." Diabetes Obes Metab, 2016;18(11):1072-1080. PMID: 27234693.
- [clinical-trial] Buse JB, et al. "Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5." Diabetes Care, 2016;39(1):92-100. PMID: 26577417.
- [clinical-trial] Grunberger G, et al. "A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial." Diabetes Obes Metab, 2016;18 Suppl 2:34-42. PMID: 27723225.
- [clinical-trial] Garg S, et al. "Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study." Diabetes Obes Metab, 2016;18 Suppl 2:43-49. PMID: 27393722.
- [clinical-trial] Harris C, et al. "Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8." Diabetes Technol Ther, 2017;19(8):463-470. PMID: 28817342.
- [clinical-trial] Hirose T, et al. "Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes." J Diabetes Investig, 2018;9(1):100-107. PMID: 28371567.
- [clinical-trial] Rosenstock J, et al. "Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials." Diabetes Obes Metab, 2016;18(11):1093-1097. PMID: 27484021.
- [clinical-trial] Ginsberg H, et al. "Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials." Diabetes Obes Metab, 2016;18(11):1089-1092. PMID: 27486125.
- [clinical-trial] Cusi K, et al. "Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes." Diabetes Obes Metab, 2016;18 Suppl 2:50-58. PMID: 27723227.
- [review] Hoogwerf BJ, et al. "Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis." Cardiovasc Diabetol, 2016;15:78. PMID: 27188479.
- [clinical-trial] Bergenstal RM, et al. "A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes." Diabetes Care, 2012;35(11):2140-7. PMID: 22787177.
- [clinical-trial] Rosenstock J, et al. "Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study." Diabetes Care, 2013;36(3):522-8. PMID: 23193209.
- [clinical-trial] Bergenstal RM, et al. "Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine." Diabetes Care, 2014;37(3):659-65. PMID: 24198302.
- [clinical-trial] Jacober SJ, et al. "Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM." Diabetes Obes Metab, 2014;16(4):351-6. PMID: 24719911.
- [clinical-trial] Sinha VP, et al. "Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects." J Clin Pharmacol, 2014;54(7):792-9. PMID: 24504686.
- [clinical-trial] Sinha VP, et al. "Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus." Diabetes Obes Metab, 2014;16(4):344-50. PMID: 24118909.
- [clinical-trial] Linnebjerg H, et al. "Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function." Clin Pharmacol Drug Dev, 2016;5(3):216-24. PMID: 27163501.
- [clinical-trial] Henry RR, et al. "Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects." Diabetes Care, 2014;37(9):2609-15. PMID: 24947791.
- [clinical-trial] Mudaliar S, et al. "Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes." Diabetes Obes Metab, 2016;18 Suppl 2:17-24. PMID: 27723226.
- [clinical-trial] Morrow LA, et al. "Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial." Diabetes Obes Metab, 2016;18(11):1065-1071. PMID: 27169522.
- [review] Muñoz-Garach A, et al. "How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes." Diabetes Ther, 2017;8(1):9-22. PMID: 27896568.
- [review] Caparrotta TM, et al. "PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue." Diabetes Obes Metab, 2014;16(5):388-95. PMID: 23941279.
- [pubmed] Moore MC, et al. "Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism." Diabetes, 2014;63(2):494-504. PMID: 24089512.
- [pubmed] Knadler MP, et al. "Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose." Drug Metab Dispos, 2015;43(10):1477-83. PMID: 26175543.
- [pubmed] Byrd RA, et al. "Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action." Toxicol Pathol, 2017;45(3):402-415. PMID: 28421968.
- [pubmed] Hirose T, et al. "Development of new basal insulin peglispro (LY2605541) ends in a disappointing result." Diabetol Int, 2016;7(1):16-17. PMID: 30603238.
Sources & Citations
Every study on this page was read from its PubMed record on October 29, 2026. Status comes from Drugs@FDA (openFDA), the EMA medicines list and ClinicalTrials.gov, read the same day. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.